Connective Tissue Disease Treatment Global Market Report 2025
상품코드:1810856
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
결합조직질환 치료 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR)은 6.1%로 311억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 고령 인구의 증가, 제약사의 R&D 투자 증가, 맞춤형 의료에 대한 수요 증가, 표적 치료제 파이프라인 증가, 환자 중심 치료 모델 중시 등에 기인할 것으로 보입니다. 이 기간 동안 주요 동향으로는 단클론항체 치료의 발전, 질병 모니터링을 위한 원격의료의 통합 확대, 생물학적 제제와 바이오시밀러로의 전환, 다중 표적 약물 요법의 개발, 학술기관과 임상연구기관의 협력 강화 등을 꼽을 수 있습니다.
자가면역질환 유병률의 증가는 향후 몇 년 동안 결합조직질환 치료 시장의 성장을 촉진할 것으로 예상됩니다. 자가면역질환은 우리 몸의 면역체계가 건강한 조직과 장기를 잘못 공격하여 발생하는 질환입니다. 발병률의 증가는 주로 면역계 기능 장애에 취약한 유전적 감수성과 이러한 상태를 유발하거나 악화시킬 수 있는 감염, 식습관, 스트레스, 독소 노출과 같은 환경적 요인이 복합적으로 작용하여 발생합니다. 결합조직질환 치료는 염증과 조직 손상을 유발하는 근본적인 면역기능 장애를 표적으로 삼아 자가면역질환 관리에 도움을 줄 수 있습니다. 이 접근법은 루푸스, 류마티스 관절염, 강피증 등 환자의 증상을 완화하고 질병의 진행을 늦추며 삶의 질을 개선하는 데 도움이 됩니다. 예를 들어, 2024년 11월 독일에 기반을 둔 헬스케어 데이터 플랫폼인 Versorgungsatlas.de는 2022년 7,324만 1,305명의 피보험자 중 630만 4,340명이 적어도 한 가지 이상의 자가면역질환 진단을 받았다고 보고했습니다. 따라서 자가면역질환 유병률의 증가는 결합조직질환 치료 시장의 성장을 촉진하고 있습니다.
결합조직질환 치료 시장의 주요 기업들은 동종 CAR-NK 세포 치료제 등 혁신적인 치료제 개발을 위한 임상시험에 집중하고 있으며, 치료 효과 향상과 자가면역질환의 미충족 수요에 대한 대응을 목표로 하고 있습니다. 동종 CAR-NK 세포 치료는 키메라 항원 수용체(CAR)로 유전자 조작된 건강한 공여자의 자연살해(NK) 세포를 사용하여 질병을 유발하는 세포를 특이적으로 표적하여 파괴하는 치료법입니다. 이 치료법은 자가면역질환에 관여하는 유해한 B세포를 제거하는 면역체계의 능력을 향상시켜 기존의 세포 치료제를 대체할 수 있는 보다 안전하고 이용하기 쉬운 대안이 될 수 있습니다. 예를 들어, 미국에 본사를 둔 임상 단계의 생명공학 기업 Nkarta Inc.는 2024년 7월 루푸스 신염에 대한 임상 중인 동종 CAR-NK 세포 치료제 NKX019를 평가하는 Ntrust-1 임상시험을 시작했습니다. 또한, CD19 발현 B세포를 선택적으로 표적으로 하는 유전자재조합 NK세포를 사용하여 자가면역질환 치료의 안전성, 접근성, 유효성을 향상시키기 위해 CD19 발현 B세포를 선택적으로 표적으로 하는 유전자재조합 NK세포를 이용한 또 다른 임상시험(Ntrust-2)을 시작하도록 FDA의 승인을 받았습니다. 유효성 향상을 목표로 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 결합조직질환 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 결합조직질환 치료 시장 : 성장률 분석
세계의 결합조직질환 치료 시장 실적 : 규모와 성장, 2019-2024
세계의 결합조직질환 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 결합조직질환 치료 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 결합조직질환 치료 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
항염증제
면역억제제
생물학적 제제와 표적요법
질병 완화 항류마티스제(DMARD)
기타 약물 클래스
세계의 결합조직질환 치료 시장 : 질환 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
전신홍반루푸스(SLE)
류마티스 관절염(RA)
경피증
피부근염
혼합성 결합조직질환(MCTD)
다발성근염
쇼그렌 증후군
혈관염
항인지질증후군(APS)
세계의 결합조직질환 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
주사제
토픽
세계의 결합조직질환 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 결합조직질환 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
재택 케어 설정
세계의 결합조직질환 치료 시장 : 하위 세분화 항염증제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
비스테로이드성 항염증제(NSAID)
전신성 코르티코스테로이드
세계의 결합조직질환 치료 시장 : 하위 세분화 면역억제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
칼시뉴린 억제제
포유류 라파마이신 표적 단백질(mTOR) 억제제
대사길항제
알킬화제
세계의 결합조직질환 치료 시장 : 하위 세분화 생물학적 제제와 표적요법(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
종양괴사인자(TNF) 억제제
인터류킨-6(IL-6) 억제제
B세포 억제제
T세포 공동자극 조절 인자
야누스 키나아제(JAK) 억제제
세계의 결합조직질환 치료 시장 : 하위 세분화 질병 완화 항류마티스제(DMARD) 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
기존 합성 질환 변성 항류마티스제(DMARD)
생물학적 질환 변성 항류마티스제(DMARD)
표적 합성 질환 변성 항류마티스제(DMARD)
세계의 결합조직질환 치료 시장 : 하위 세분화 기타 약물 클래스(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
진통제
항말라리아제
항생제
단클론항체
제7장 지역별·국가별 분석
세계의 결합조직질환 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 결합조직질환 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
결합조직질환 치료 시장 : 경쟁 구도
결합조직질환 치료 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
AstraZeneca PLC
Novartis AG
GlaxoSmithKline(GSK) PLC
Eli Lilly and Company
Amgen Inc.
Biogen Inc.
Vertex Pharmaceuticals
UCB S.A.
Hikma Pharmaceuticals PLC
Innovent Biologics Inc.
RemeGen Co. Ltd
Kymera Therapeutics
Adicet Bio
Equillium Inc.
Stem Cell Care India
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
결합조직질환 치료 시장 2029 : 새로운 기회를 제공하는 국가
결합조직질환 치료 시장 2029 : 새로운 기회를 제공하는 부문
결합조직질환 치료 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Connective tissue disease treatment involves managing a group of autoimmune or inflammatory disorders that impact connective tissues like joints, skin, muscles, and internal organs. The goal is to reduce inflammation, regulate immune system activity, alleviate symptoms such as pain and fatigue, and prevent disease progression and organ damage.
The primary drug classes for treating connective tissue diseases include anti-inflammatory drugs, immunosuppressants, biologics and targeted therapies, disease-modifying anti-rheumatic drugs (DMARDs), and others. Anti-inflammatory drugs help decrease inflammation, pain, and swelling by inhibiting the body's inflammatory response and are widely used in managing these diseases. These medications are prescribed for various conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, dermatomyositis, mixed connective tissue disease (MCTD), polymyositis, Sjogren's syndrome, vasculitis, and antiphospholipid syndrome (APS). Administration routes include oral, injectable, and topical forms. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users in hospitals, clinics, and homecare settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The connective tissue disease treatment market research report is one of a series of new reports from The Business Research Company that provides connective tissue disease treatment market statistics, including the connective tissue disease treatment industry global market size, regional shares, competitors with the connective tissue disease treatment market share, detailed connective tissue disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the connective tissue disease treatment industry. These connective tissue disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The connective tissue disease treatment market size has grown strongly in recent years. It will grow from $23.08 billion in 2024 to $24.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to the rising prevalence of autoimmune disorders, increased awareness of early diagnosis, improvements in healthcare infrastructure in developing regions, greater adoption of biologic therapies, and expanding insurance coverage for managing chronic diseases.
The connective tissue disease treatment market size is expected to see strong growth in the next few years. It will grow to $31.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth expected in the forecast period can be attributed to an expanding geriatric population, increased research and development investments by pharmaceutical companies, rising demand for personalized medicine, a growing pipeline of targeted therapies, and a focus on patient-centered care models. Key trends during this period include advancements in monoclonal antibody therapies, greater integration of telemedicine for disease monitoring, a shift toward biologics and biosimilars, development of multi-targeted drug regimens, and enhanced collaboration between academic and clinical research institutions.
The rising incidence of autoimmune diseases is expected to drive the growth of the connective tissue disease treatment market in the coming years. Autoimmune diseases occur when the body's immune system mistakenly attacks healthy tissues and organs. The increasing incidence is mainly caused by a combination of genetic susceptibility, which makes some individuals more vulnerable to immune system malfunctions, and environmental factors such as infections, diet, stress, and exposure to toxins that can trigger or worsen these conditions. Treatments for connective tissue diseases help manage autoimmune disorders by targeting the underlying immune dysfunction that leads to inflammation and tissue damage. This approach helps alleviate symptoms, slow disease progression, and improve the quality of life for patients with conditions like lupus, rheumatoid arthritis, and scleroderma. For example, in November 2024, Versorgungsatlas.de, a Germany-based healthcare data platform, reported that in 2022, 6,304,340 out of 73,241,305 insured individuals were diagnosed with at least one autoimmune disease, reflecting a raw prevalence rate of 8.61%. Therefore, the rising incidence of autoimmune diseases is fueling the growth of the connective tissue disease treatment market.
Key companies in the connective tissue disease treatment market are focusing on clinical trials to develop innovative therapies such as allogeneic CAR-NK cell therapy, aiming to improve treatment effectiveness and address unmet needs in autoimmune diseases. Allogeneic CAR-NK cell therapy involves using natural killer (NK) cells from healthy donors that are genetically engineered with chimeric antigen receptors (CAR) to specifically target and destroy disease-causing cells. This therapy boosts the immune system's ability to eliminate harmful B-cells involved in autoimmune conditions and offers a potentially safer and more accessible alternative to conventional cell therapies. For instance, in July 2024, Nkarta Inc., a US-based clinical-stage biotech firm, initiated the Ntrust-1 clinical trial to assess NKX019, an investigational allogeneic CAR-NK cell therapy for lupus nephritis. The company also received FDA approval to start a separate trial (Ntrust-2) targeting systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis, aiming to improve safety, accessibility, and efficacy in autoimmune disease treatment by using genetically engineered NK cells that selectively target CD19-expressing B-cells.
In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition was intended to expand Amgen's footprint in the rare and autoimmune disease market by incorporating Horizon Therapeutics' portfolio of innovative and rapidly growing biologic therapies, including Tepezza, Krystexxa, and Uplizna. The deal strengthens Amgen's pipeline, diversifies its revenue streams, and enhances its leadership position in specialty therapeutics. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company specializing in treatments for Sjogren's syndrome and rheumatoid arthritis.
Major players in the connective tissue disease treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) PLC, Eli Lilly and Company, Amgen Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Hikma Pharmaceuticals PLC, Innovent Biologics Inc., RemeGen Co. Ltd, Kymera Therapeutics, Adicet Bio, Equillium Inc., and Stem Cell Care India.
North America was the largest region in the connective tissue disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in connective tissue disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the connective tissue disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The connective tissue disease treatment market includes revenues earned by entities by providing services such as medication administration, physical rehabilitation, patient education, genetic counselling, long-term disease monitoring, and laboratory testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The connective tissue disease treatment market also includes sales of monoclonal antibodies, biologic agents, and corticosteroids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Connective Tissue Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on connective tissue disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for connective tissue disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The connective tissue disease treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Anti-Inammatory Drugs; Immunosuppressants; Biologics And Targeted Therapy; Disease-Modifying Anti-Rheumatic Drugs (DMARDs); Other Drug Classes
3. Connective Tissue Disease Treatment Market Trends And Strategies
4. Connective Tissue Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Connective Tissue Disease Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Connective Tissue Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Connective Tissue Disease Treatment Market Growth Rate Analysis
5.4. Global Connective Tissue Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Connective Tissue Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Connective Tissue Disease Treatment Total Addressable Market (TAM)
6.1. Global Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Inammatory Drugs
Immunosuppressants
Biologics And Targeted Therapy
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Other Drug Classes
6.2. Global Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis (RA)
Scleroderma
Dermatomyositis
Mixed Connective Tissue Disease (MCTD)
Polymyositis
Sjogren's Syndrome
Vasculitis
Antiphospholipid Syndrome (APS)
6.3. Global Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Topical
6.4. Global Connective Tissue Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Connective Tissue Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Homecare Settings
6.6. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Anti-Inflammatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Systemic Corticosteroids
6.7. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Calcineurin Inhibitors
Mammalian Target Of Rapamycin (mTOR) Inhibitors
Antimetabolites
Alkylating Agents
6.8. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Biologics And Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor Necrosis Factor (TNF) Inhibitors
Interleukin-6 (IL-6) Inhibitors
B-Cell Inhibitors
T-Cell Co-Stimulation Modulators
Janus Kinase (JAK) Inhibitors
6.9. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Disease-Modifying Anti-Rheumatic Drugs (DMARDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.10. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Analgesics
Antimalarial Drugs
Antibiotics
Monoclonal Antibodies
7. Connective Tissue Disease Treatment Market Regional And Country Analysis
7.1. Global Connective Tissue Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Connective Tissue Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Connective Tissue Disease Treatment Market
9.1. China Connective Tissue Disease Treatment Market Overview
9.2. China Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Connective Tissue Disease Treatment Market
10.1. India Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Connective Tissue Disease Treatment Market
11.1. Japan Connective Tissue Disease Treatment Market Overview
11.2. Japan Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Connective Tissue Disease Treatment Market
12.1. Australia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Connective Tissue Disease Treatment Market
13.1. Indonesia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Connective Tissue Disease Treatment Market
14.1. South Korea Connective Tissue Disease Treatment Market Overview
14.2. South Korea Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Connective Tissue Disease Treatment Market
15.1. Western Europe Connective Tissue Disease Treatment Market Overview
15.2. Western Europe Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Connective Tissue Disease Treatment Market
16.1. UK Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Connective Tissue Disease Treatment Market
18.1. France Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Connective Tissue Disease Treatment Market
21.1. Eastern Europe Connective Tissue Disease Treatment Market Overview
21.2. Eastern Europe Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Connective Tissue Disease Treatment Market
22.1. Russia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Connective Tissue Disease Treatment Market
23.1. North America Connective Tissue Disease Treatment Market Overview
23.2. North America Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Connective Tissue Disease Treatment Market
24.1. USA Connective Tissue Disease Treatment Market Overview
24.2. USA Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Connective Tissue Disease Treatment Market
26.1. South America Connective Tissue Disease Treatment Market Overview
26.2. South America Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Connective Tissue Disease Treatment Market
27.1. Brazil Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Connective Tissue Disease Treatment Market
28.1. Middle East Connective Tissue Disease Treatment Market Overview
28.2. Middle East Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Connective Tissue Disease Treatment Market
29.1. Africa Connective Tissue Disease Treatment Market Overview
29.2. Africa Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Connective Tissue Disease Treatment Market Competitive Landscape And Company Profiles
